{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"76"}]}],"title":"Complete/Cure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"29"}]}],"title":"Non-response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"Inevaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements.","groups":[{"description":"Arm 1: Methotrexate 30 mg/m2 IM weekly","id":"OG000","title":"Arm 1: Methotrexate 30 mg/m2 IM Weekly"},{"description":"Arm 2: Dactinomycin 1.25 mg/m2 IV push every 2 weeks","id":"OG001","title":"Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible patients who received a random treatment allocation","reportingStatus":"POSTED","timeFrame":"Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.","title":"Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay","type":"PRIMARY","unitOfMeasure":"Participants"}